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Aims To evaluate population-based electronic health record (EHR) definitions of atrial fibrillation (AF) and valvular heart
disease (VHD) subtypes, time trends in prevalence and prognosis.
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Methods
and results
A total of 76 019 individuals with AF were identified in England in 1998–2010 in the CALIBER resource, linking pri-
mary and secondary care EHR. An algorithm was created, implemented, and refined to identify 18 VHD subtypes
using 406 diagnosis, procedure, and prescription codes. Cox models were used to investigate associations with a
composite endpoint of incident stroke (ischaemic, haemorrhagic, and unspecified), systemic embolism (SSE), and
all-cause mortality. Among individuals with AF, the prevalence of AF with concomitant VHD increased from 11.4%
(527/4613) in 1998 to 17.6% (7014/39 868) in 2010 and also in individuals aged over 65 years. Those with mechani-
cal valves, mitral stenosis (MS), or aortic stenosis had highest risk of clinical events compared to AF patients with
no VHD, in relative [hazard ratio (95% confidence interval): 1.13 (1.02–1.24), 1.20 (1.05–1.36), and 1.27 (1.19–
1.37), respectively] and absolute (excess risk: 2.04, 4.20, and 6.37 per 100 person-years, respectively) terms. Of the
95.2% of individuals with indication for warfarin (men and women with CHA2DS2-VASc >_1 and >_2, respectively),
only 21.8% had a prescription 90 days prior to the study.
...................................................................................................................................................................................................
Conclusion Prevalence of VHD among individuals with AF increased from 1998 to 2010. Atrial fibrillation associated with aor-
tic stenosis, MS, or mechanical valves (compared to AF without VHD) was associated with an excess absolute risk
of stroke, SSE, and mortality, but anticoagulation was underused in the pre-direct oral anticoagulant (DOAC) era,
highlighting need for urgent clarity regarding DOACs in AF and concomitant VHD.
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Introduction
Varying definitions across practice, guidelines, observational studies,
and trials1 make ‘valvular’ atrial fibrillation (AF) an obsolete term.
European AF guidelines consider valvular heart disease (VHD) as me-
chanical heart valves (MechV) or mitral stenosis (MS),2 which direct
oral anticoagulant (DOAC) trials excluded.1
Atrial fibrillation3 and VHD4 are increasing globally, occurring to-
gether in 2–31% of AF.5 Despite consistent data for MechV and MS,6
AF studies to-date are neither representative,1,7,8 nor include all
VHD subtypes6 (e.g. aortic stenosis, AS1) nor time trends (e.g.
increases in prevalence of AF with AS or mitral regurgitation, MR, vs.
reductions in rheumatic AF).
Compared to AF without VHD,6 stroke and systemic embolism
(SSE) risk is increased in AF with MechV and MS,9 with similar risk fac-
tor profiles.5 Costs of not anticoagulating are likely to be high10 in
VHD. Warfarin is recommended in all VHD subtypes with AF, based
on stroke and bleeding risk,1 whereas DOACs lack conclusive trial
evidence. However, the full range of VHD remains unstudied in the
pre-DOAC era.
Electronic health records (EHRs) could address these uncertain-
ties with greater sample size and generalizability than other study
designs.11 Valvular heart disease has been studied in EHR,12 but with-
out distinguishing subtypes in AF. We investigated: (i) feasibility of us-
ing EHR to identify AF with VHD, (ii) temporal trends in prevalence
of VHD subtypes with AF 1998–2010 (prior to routine DOAC use),
and (iii) prognosis of VHD subtypes of AF.
Methods
Data sources
CALIBER,13 connecting mortality (Office of National Statistics, ONS), pri-
mary (Clinical Practice Research Datalink, CPRD), and secondary care
(Hospital Episode Statistics) data, is representative of the UK population
by age, sex, ethnicity,14 and mortality,15 providing valid risk estimates as-
sociated with cardiovascular diseases16–20 (SR1). Coding involves four
controlled clinical terminologies: Read (primary care diagnoses/proce-
dures, mapping to SNOMED-CT) (SR2), prescriptions (British National
Formulary, BNF, and primary care) (SR3), ICD-10 (secondary care diag-
noses/mortality) (SR4), and OPCS-4 (secondary care procedures) (SR5).
Study population
A validated EHR AF phenotype in primary and/or secondary care was
used (1998–2010) (SR6), including individuals aged >_18 years, with any
AF pattern and >_1 year of primary care follow-up prior to earliest coded
AF during the study period (‘baseline’).
Electronic health record phenotype
algorithm
We followed CALIBER guidelines for algorithm development (SR7);
combining informatics (with re-usable scripts), clinical review of codes/
algorithms, and validation. The final algorithm for acquired VHD (exclud-
ing congenital) combined 406 diagnosis, procedure, prescription, and
valve replacement codes (Figure 1; Supplementary material online,
Appendix), classifying the single most relevant VHD, in order of replace-
ments, repairs, and stenosis/regurgitation (supported by ROCKET-AF)
(SR8). Recurrences were unnecessary for confirming events since individ-
uals with less frequently captured data may be systematically excluded.
Risk factors
CHADS2 (SR9) and CHA2DS2VASc variables (SR10) were extracted: age
and sex16: primary care registration information; heart failure (HF)
(SR11), diabetes mellitus (DM type I, II, and unclassified),17 SSE/transient
ischaemic attack (TIA), and vascular disease (myocardial infarction19 or
peripheral artery disease): Read/ICD-10; hypertension18: Read/ICD-10,
>_2 blood pressure measurements >_140/90 mmHg or repeat anti-
hypertensive prescriptions. Eligibility for oral anticoagulant (OAC) was
determined by CHADS2/CHA2DS2VASc. Oral anticoagulant use was
based on BNF warfarin codes or International Normalized Ratio (INR)
tests <_90 days before study entry. Bleeding risk was ascertained: hyper-
tension, age >75 years, prior haemorrhagic stroke, and labile INR (>_5 at
least once).
Primary outcomes
Primary composite outcome was SSE (including ischaemic, haemorrhagic,
and unspecified stroke) or all-cause mortality; a common trial primary
endpoint (SR12-SR15). Follow-up was until transfer/last visit in primary
care, when secondary care was censored to align data sources, avoiding
missing events and immortal follow-up time.
Statistical analysis
Analysis was by baseline VHD: (i) replacement; (ii) repair; (iii) MS, (iv) AS,
(v) MR, or (vi) aortic regurgitation (AR). Tricuspid and pulmonary valve
disorders were analysed together due to limited numbers (n= 277)
(Table 1). Baseline characteristics were analysed by VHD. Prevalence was
calculated at monthly/yearly intervals 1998–2010, dividing total number
with prevalent VHD by total number at risk. LOESS (LOcally wEighted
Scatterplot Smoothing) lines were fitted to identify temporal trends in
prevalence, making no assumption about data distribution (SR16).
Incident cases were included in prevalence calculation over time, not in
risk modelling which considered baseline VHD.
For prognostic validation of AF with VHD subtypes, we modelled
associations (vs. AF without VHD) with the primary endpoint, expecting
higher SSE risk with MechV and MS.6 Incrementally adjusted Cox
What’s new?
• In the first large-scale electronic health record (EHR) study of
atrial fibrillation (AF) and valvular heart disease (VHD), differ-
ent subtypes of VHD had high prevalence and high risk of ad-
verse events.
• The burden of VHD increased from 1998 to 2010 among indi-
viduals with AF, possibly due to increased diagnostic sensitivity,
increased reporting of milder VHD or longevity with VHD.
• Among VHD subtypes, AF with mechanical valves, mitral ste-
nosis, and aortic stenosis had greatest thromboembolic risk,
with worst outcomes in aortic stenosis.
• There was low oral anticoagulant utilization in the pre-direct
oral anticoagulant (DOAC) (direct anticoagulant) era, despite
high predicted and actual stroke/mortality risks, and particu-
larly in the highest risk patients (e.g. aortic stenosis).
• Our EHR VHD phenotype provides transparent, reproducible
and interoperable definitions for future EHR analyses, including
international datasets.
• Prognostic differences across AF/VHD subtypes support tar-
geted DOAC trials in specific VHD subpopulations.
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Figure 1 Electronic health record algorithm to classify AF and concomitant VHD. Flow diagram illustrates electronic health record algorithm for
classifying individuals with AF and prevalent valvular disease at study index into one of 18 valvular AF subtypes. The algorithm considers first valve
replacements, followed by valve repairs and then valve diseases, which are recorded at any prior time point in an individual’s medical history. The al-
gorithm is underpinned by 406 diagnosis, procedure, and prescription codes from the Read, ICD-10, OPCS-4, and BNF systems. Full code list and
electronic health record algorithm provided in Supplementary material online, Appendix. AF, atrial fibrillation; VHD, valvular heart disease.
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regression with model assumptions and goodness-of-fit were assessed
graphically, confirming proportionality over time with scaled Schoenfeld
residuals. Adjustment was for age and sex (Model 1); Model 1 and base-
line warfarin prescriptions (Model 2); and Model 2 and CHA2DS2VASc
factors (Model 3) (Supplementary material online, Table S2). Interaction
testing was conducted between baseline VHDs and key confounders:
age, sex, warfarin, and prior SSE/TIA. All models stratified by primary care
practice, accounting for potential local differences in the application of
coding or management. Stata/SE 13.1 was used for data analyses and R
3.2.0 for figures.
Ethics
The study was approved by the MHRA (UK) Independent Scientific
Advisory Committee (12_165), under Section 251 (NHS Social Care Act
2006).
Results
Among 76 019 individuals with AF, we used 165 diagnosis and 205
procedure codes (370 total) for VHD across Read (235; 63.5%),
ICD-10 (49; 13.2%), and OPCS-4 (86; 23.2%) (Supplementary mate-
rial online, Table S1). A total of 12 751 (16.8%) had AF and VHD;
8623 (11.3%) had prevalent VHD, median (interquartile range, IQR)
3.1 (8.9) years before study entry; and 4128 (5.4%) had incident VHD
with median 1.4 (3.4) years of follow-up. A total of 2578 (3.3%) had
valve replacements; 1902 (2.5%) prevalent at baseline; and 676
(0.9%) over follow-up.
A total of 67 396 (88.7%) had no VHD at baseline, 1207 (1.6%)
had MechV, 695 (0.9%) bioprosthetic valve replacement, 434 (0.6%)
valve repair, 527 (0.7%) MS, 2374 (3.1%) MR, 974 (1.3%) other mitral
disorders, 1494 (2.0%) AS, 444 (0.6%) AR, and 197 (0.3%) other aor-
tic disorders. Among 4128 with incident VHD, the affected valve was
mitral in 2700 (65.4%), aortic in 1288 (31.2%), tricuspid in 398 (9.6%),
pulmonary in 48 (1.2%), and unspecified in 63 (1.5%) (Supplementary
material online, Figure S1).
Baseline characteristics
Median (IQR) age was 77.7 (15.0) years, 49.1% female with median
(IQR) 2.2 (4.2) years follow-up. Comorbidities were common, e.g.
26.1% HF, 82.7% hypertension, 14.2% DM, and 19.8% vascular dis-
ease. About 67.6% of the population had CHADS2 >_2 and 88.6% had
CHA2DS2-VASc >_2. Warfarin prescription <_90 days prior to the
study was low: 22.6% and 21.8% (indicated by CHADS2 and
CHA2DS2-VASc, respectively) (Table 1). When indicated regardless
of AF (i.e. MechV and MS), warfarin use was 65.9%.
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Figure 2 Trends in prevalence of valvular heart disease among 76 019 cases of AF (1998–2010) by age groups. AF, atrial fibrillation.
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In AF and VHD, rates of HF (45.7% vs. 23.6%), hypertension
(89.8% vs. 81.8%), and CHA2DS2-VASC scores [mean (standard de-
viation, SD) 4.1 (1.7) vs. 3.7 (1.8)] were higher, compared to AF with-
out VHD. Individuals with MechV were youngest [median (IQR): 70.5
(13.4) years] with highest warfarin use (68.7%). Individuals with MS
were 75.3% female, had highest SSE/TIA prevalence (24.5%), and
warfarin use was 59.6%. Individuals with AS were older [median
(IQR) 82.2 (11.3) years], had high DM (17.1%), and vascular disease
(28.9%) prevalence, high CHA2DS2VASC score [mean (SD): 4.5
(1.6)], and lowest warfarin use (20.5%).
Prevalence and incidence
Valvular heart disease prevalence increased from 11.4% to 17.6%
(1998–2010), particularly age >65 years (Figure 2). Prevalence in-
creased for bioprosthetic replacements (0.7% in 1998–99 to 2.1%
in 2009–10), valve repairs (0.9–2.2%), MR (4.9–8.1%), AS (2.3–
5.0%), and AR (1.2–2.3%). Prevalence increased for MechV from
2.1% to 2.6% (1998–99 to 2002–03), then plateaued, and de-
creased for MS from 2.0% to 1.4% (1998–99 to 2009–10)
(Figure 3).
Risks of SSE and mortality
A total of 31 934 endpoints (9.2% ischaemic stroke, 13.8% unspecified
stroke, 1.7% SE, 2.3% haemorrhagic stroke, 73.1% mortality) occurred
in 3764 (11.8%) individuals with AF and VHD. Absolute SSE/mortality
risk was high, compared to AF without VHD. Only AF with biopros-
thetic replacements or valve repair had lower risk (13.9 and 15.3 per
100 person-years, respectively) compared to AF without VHD (18.2
per 100 person-years) (Supplementary material online, Table S2). The
highest risk was in AS, MS, AR, and MechV (24.6, 22.4, 21.4, and 20.2
per 100 person-years respectively). Compared to AF without VHD,
MechV, MS, and AS carried excess risk of the composite endpoint of
2.04, 4.20, and 6.37 per 100 person-years, respectively.
Compared with AF without VHD, MechV, MS, and AS carried
greatest risk for the primary endpoint [hazard ratio (HR) (95% confi-
dence interval): 1.13 (1.02–1.24); 1.20 (1.05–1.36); and 1.27 (1.19–
1.37), respectively] after adjustment for age, sex, warfarin use, and
CHA2DS2VASc risk factors, while bioprosthetic replacements car-
ried lower risk [HR 0.78 (0.68–0.88)] (Table 2, Figure 4,
Supplementary material online, Table S2). For MechV, there was no
difference between mitral and aortic (HR 1.08, 0.91–1.29 and HR
Figure 3 Trends in prevalence of valvular AF subtypes (1998–2010). AF, atrial fibrillation.
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1.08, 0.94–1.24, respectively], but increased risk with ‘unspecified’
(HR 1.26, 1.05–1.51). For bioprosthetic replacements, aortic
appeared favourable (HR 0.93, 0.66–1.33 for mitral; HR 0.76, 0.65–
0.90 for aortic; HR 0.77, 0.59–1.00 for unspecified, respectively).
Discussion
In the first large-scale EHR study of AF and VHD, different VHD sub-
types had high prevalence and high risk of adverse events, yet low
OAC utilization. Among 76 019 AF cases, there was high VHD bur-
den (11.3% at baseline), increasing over time (11.4% in 1998 to 17.6%
in 2010). Among VHD subtypes, AF with MechV, MS, and AS had
greatest thromboembolic risk, with worst outcomes in AS (Figure 5).
Cohorts [e.g. Framingham: 1544 incident AF cases (SR17)]
and registries [e.g. EuroHeart Survey: 5333 AF patients (SR18)]
lack scale to investigate VHD subtypes. Registries and trials sup-
port the observed high risk with AF and AS.8 Our algorithm’s
validity is implied by replication of known associations of higher
....................................................................................................................................................................................................................
Table 2 Subtypes of AF with concomitant valvular heart disease and risk of incident stroke, systemic embolism, and
all-cause mortality
Subtypes of AF Individuals Events HR (95% CI)a HR (95% CI)b HR (95% CI)c
No heart valve disease 67 396 28 169 Reference Reference Reference
Any heart valve disease 8623 3764 1.17 (1.13–1.21) 1.20 (1.16–1.25) 1.08 (1.04–1.12)
Mechanical valve replacement 1207 465 1.17 (1.07–1.28) 1.26 (1.14–1.38) 1.13 (1.02–1.24)
Bioprosthetic valve replacement 695 234 0.82 (0.72–0.94) 0.84 (0.74–0.95) 0.78 (0.68–0.88)
Valve repair 434 122 0.88 (0.74–1.06) 0.93 (0.78–1.12) 0.84 (0.70–1.01)
Mitral stenosis 527 250 1.25 (1.10–1.42) 1.34 (1.18–1.52) 1.20 (1.05–1.36)
Mitral regurgitation 2374 1050 1.14 (1.07–1.21) 1.17 (1.10–1.25) 1.05 (0.99–1.12)
Other mitral disorder 974 421 1.19 (1.08–1.32) 1.22 (1.11–1.35) 1.09 (0.99–1.20)
Aortic stenosis 1494 794 1.41 (1.32–1.52) 1.42 (1.32–1.53) 1.27 (1.19–1.37)
Aortic regurgitation 444 215 1.23 (1.07–1.41) 1.23 (1.08–1.41) 1.13 (0.98–1.29)
Other aortic disorder 197 94 1.14 (0.93–1.39) 1.15 (0.94–1.41) 1.10 (0.90–1.35)
All stratified on primary care practice.
AF, atrial fibrillation; HR (95% CI), hazard ratio (95% confidence interval).
aAdjusted for age and sex.
bAdjusted for Model 1 þ baseline warfarin prescription.
cModel 2 þ heart failure, hypertension, diabetes mellitus, stroke, transient ischaemic attack, or system embolism, vascular disease.
No valve disease
Individuals
67396
Events
28169
aHR [95% CI]
reference
8623 3764 1.08 [1.04, 1.12]
1207 465 1.13 [1.02, 1.24]
695 234 0.78 [0.68, 0.88]
434 122 0.84 [0.70, 1.01]
527 250 1.20 [1.05, 1.36]
2374 1050 1.27 [1.19, 1.37]
974 421 1.05 [0.99, 1.12]
1494 794 1.13 [0.98, 1.29]
444 215 1.09 [0.99, 1.20]
197 94 1.10 [0.90, 1.35]
Any valve disease
Prosthetic valve
Bioprosthetic valve
Valve repair
Mitral stenosis
Aortic stenosis
Mitral regurgitation
Aortic regurgitation
Mitral disorder, nos
Aortic disorder, nos
0.7 0.8 0.9 1.0
Individuals with AF and VHD subtypes (vs. no VHD)
1.1 1.2 1.3 1.4
Figure 4 AF and VHD subtypes and adjusted risk of incident stroke, systemic embolism, and all-cause mortality. Reference category: patients with
AF and no record of valvular heart disease. Hazard ratios adjusted for age, sex, warfarin, heart failure, hypertension, diabetes mellitus, stroke, transient
ischaemic attack or systemic embolism, and vascular disease. AF, atrial fibrillation; aHR (95% CI), adjusted hazard ratio (95% confidence interval);
VHD, valvular heart disease; nos, not otherwise specified.
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SSE/mortality risk with MechV and MS,6 consistent with guideline
definitions2 (SR19), DOAC trials (SR12-SR15), and recent
reviews.6
There was sufficient resolution to distinguish between specific
valve(s) (98.5%) and between MechV and bioprosthetic replacements
(84.3%). For ‘unspecified’, ‘mechanical’, or ‘bioprosthetic’ could be in-
ferred by differences in age and warfarin use. Codes for rheumatic
VHDs were seldom used, perhaps reflecting disease reductions in in-
dustrialized countries (SR20). As previously shown (SR21, SR22), MR
and AS, associated with ageing, were most common with annual
increases in prevalence. MS was the only VHD with decreasing preva-
lence. Echocardiography rates (Supplementary material online, Table
S3) increased 1998–2010 at all ages (5.5–65.4% in <65 years, 1.8–
48.3% in >85 years), arguing against age-specific diagnostic approaches.
Increased VHD prevalence (e.g. MR) may reflect increased diagnostic
sensitivity, increased reporting of milder VHD or longevity with VHD.
Implications
Clinical
First, there was pre-DOAC underuse of warfarin, despite high pre-
dicted and actual stroke/mortality risks, particularly with AS, MS, and
MechV. Oral anticoagulant use has increased in recent years (SR23),
but sufficiently powered DOAC trials in AF with VHD are lacking. In
the absence of contraindications, warfarin should be initiated and
continued lifelong1 (SR24). Second, increased mortality risk in aortic
and mitral VHD suggest alternative VHD/AF patient pathways, e.g.
VHD surveillance should incorporate regular AF screening and echo-
cardiography in AF should emphasize VHD exclusion. Third, prog-
nostic differences across AF/VHD subtypes support targeted DOAC
trials in specific VHD subpopulations.
Research
First, given disparate exclusion criteria in DOAC trials (SR12-SR15),
the significant thromboembolic risk with MechV and MS informs fu-
ture trials. Second, our VHD phenotype provides transparent, repro-
ducible, and interoperable definitions for future EHR analyses,
including international datasets. The code list is useful, not only for
AF, but also VHD, which is timely, given that new 2017 European
VHD guidelines pinpoint extensive evidence gaps in risk stratification
and comparative effectiveness of different surgical interventions
(SR25). Third, underuse of rheumatic and non-rheumatic VHD codes
warrants further study.
Strengths
Major strengths are generalizability, proven validity of EHRs in
CALIBER,13 considerably larger sample size than prior studies
(SR26), and replication of observed associations between VHD/AF
and poorer prognosis6 (SR27).
Limitations
i. EHR data: AF and VHD cases may have been missed/misclassified
due to unreliable coding for VHD severity, electrocardiogram, and
echocardiography, despite GP questionnaire (positive predictive
value = 96%) (SR28) and external (median 89% CPRD diagnoses) val-
idation (SR29). Given poor prognosis in MS, all degrees of severity
are likely to be recorded, whereas for MR or AS, capture of severe
forms is more likely, leading to overestimation of impact. Electronic
health record (including imaging) validation at scale (e.g. GP/patient
re-contact studies) is required in the UK, but currently impractical.
ii. Study design: Unmeasured confounding is possible in observational
analyses. Relative importance of AF vs. VHD was not assessed since
individuals without AF were excluded.
iii. VHD severity: Our algorithm prioritized stenosis before regurgitation,
based on prior data (SR8), which may be inappropriate (e.g. mild AS
vs. severe MR), and omits >_one affected valve, e.g. the most prevalent
baseline VHD was MR (4.4%), decreasing to 3.1% with our algorithm.
iv. Rheumatic disease: For rheumatic VHD, if MS is more common than
MR, it is probably associated with higher mortality risk, independent
of AF.
v. Prescriptions: Low OAC rates may reflect lack of secondary care pre-
scription capture, or our more representative cohort (older, higher
risk and less likely to receive OAC). Antiplatelet use was unavailable
but likely to be significant, given high vascular disease and stroke/TIA
rates, and guideline recommendations in low/intermediate-risk
Valve disease
Any valve disease
Mechanical valve
Bioprosthetic valve
Valve repair
Mitral stenosis
Mitral regurgitation
Mitral-other
Aortic stenosis
Aortic regurgitation
Aortic-other
69.4
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20.3
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3.5
4.0
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4.1
4.5
4.1
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3.71.08 [1.04, 1.12]
1.13 [1.02, 1.24]
0.78 [0.68, 0.88]
0.84 [0.70, 1.01]
1.20 [1.05, 1.36]
1.05 [0.99, 1.12]
1.09 [0.99, 1.20]
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1.13 [0.98, 1.29]
1.10 [0.90, 1.35]
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Figure 5 Subtypes of AF with concomitant valvular heart disease and risk of incident stroke, systemic embolism, and all-cause mortality. OAC,
oral anticoagulation.
8 A. Banerjee et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/advance-article-abstract/doi/10.1093/europace/euz220/5549426 by U
niversity of Birm
ingham
 user on 18 N
ovem
ber 2019
individuals. However, event rates in low/intermediate-risk patients
were low (5.7 and 2.9 per 100 person-years for CHADS2 <2 and
CHA2DS2VASc <2, respectively).
Conclusion
High prevalence of VHD in AF patients, associated with increased
risk of adverse events, is a major and growing burden of disease, yet
patients are sub-optimally treated with oral anticoagulation. We re-
port a transparent and reproducible EHR algorithm, providing new
insights into VHD subtypes in AF and key implications for future
research.
Supplementary material
Supplementary material is available at Europace online.
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